



BACARA TRIPLE

Version 1 / IRL
102000027454

1/13
Revision Date: 26.09.2019
Print Date: 26.09.2019

SECTION 1: IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND OF THE COMPANY/UNDERTAKING

1.1 Product identifier

Trade name BACARA TRIPLE
Product code (UVP) 81740143

1.2 Relevant identified uses of the substance or mixture and uses advised against

Use Herbicide

1.3 Details of the supplier of the safety data sheet

Supplier Bayer CropScience Ltd
Bayer Ltd
The Atrium, Blackthorn Road
Sandyford
Dublin 18
Ireland

Telephone +353-1-2999313

Responsible Department Email: ukcropsupport@bayer.com

1.4 Emergency telephone no.

Emergency telephone no. 00800 1020 3333 (24 hr)

SECTION 2: HAZARDS IDENTIFICATION

2.1 Classification of the substance or mixture

Classification in accordance with Regulation (EC) No 1272/2008 on classification, labelling and packaging of substances and mixtures, as amended.

Specific target organ toxicity - repeated exposure: Category 2
H373 May cause damage to organs (Nervous system) through prolonged or repeated exposure if swallowed.

Acute aquatic toxicity: Category 1
H400 Very toxic to aquatic life.

Chronic aquatic toxicity: Category 1
H410 Very toxic to aquatic life with long lasting effects.

2.2 Label elements

Labelling in accordance with Regulation (EC) No 1272/2008 on classification, labelling and packaging of substances and mixtures, as amended.

Hazard label for supply/use required.

Hazardous components which must be listed on the label:

- Flufenacet
- Diflufenican
- Metribuzin

**BACARA TRIPLE**Version 1 / IRL
1020000274542/13
Revision Date: 26.09.2019
Print Date: 26.09.2019**Signal word:** Warning**Hazard statements**

- H373 May cause damage to organs (Nervous system) through prolonged or repeated exposure if swallowed.
- H410 Very toxic to aquatic life with long lasting effects.
- EUH208 Contains Flufenacet, 1,2-benzisothiazolin-3-one, reaction mass of 5-chloro-2- methyl-2H-isothiazol-3-one and 2-methyl-2H-isothiazol-3- one (3:1). May produce an allergic reaction.
- EUH401 To avoid risks to human health and the environment, comply with the instructions for use.

Precautionary statements

- P260 Do not breathe dust/ fume/ gas/ mist/ vapours/ spray.
- P280 Wear protective gloves/ protective clothing/ eye protection/ face protection.
- P308 + P311 IF exposed or concerned: Call a POISON CENTER/ doctor/ physician.
- P391 Collect spillage.
- P501 Dispose of contents/container to a licensed hazardous waste disposal contractor or collection site, except for triple rinsed empty containers which can be disposed of as non-hazardous waste.

2.3 Other hazards

No other hazards known.

SECTION 3: COMPOSITION/INFORMATION ON INGREDIENTS**3.2 Mixtures****Chemical nature**Suspension concentrate (=flowable concentrate)(SC)
Diflufenican 171 g/l; Flufenacet 171 g/l; Metribuzin 64 g/l**Hazardous components**

Hazard statements according to Regulation (EC) No. 1272/2008

Name	CAS-No. / EC-No. / REACH Reg. No.	Classification	Conc. [%]
		REGULATION (EC) No 1272/2008	
Diflufenican	83164-33-4	Aquatic Chronic 3, H412	14.60
Flufenacet	142459-58-3	STOT RE 2, H373 Skin Sens. 1, H317 Aquatic Acute 1, H400 Aquatic Chronic 1, H410 Acute Tox. 4, H302	14.60
Metribuzin	21087-64-9 244-209-7	Aquatic Acute 1, H400 Aquatic Chronic 1, H410 Acute Tox. 4, H302	5.47

**BACARA TRIPLE**Version 1 / IRL
102000027454

3/13

Revision Date: 26.09.2019
Print Date: 26.09.2019

1,2-Benzisothiazol-3(2H)-one	2634-33-5 220-120-9 01-2120761540-60-xxxx	Acute Tox. 4, H302 Acute Tox. 2, H330 Skin Irrit. 2, H315 Eye Dam. 1, H318 Skin Sens. 1, H317 Aquatic Acute 1, H400 Aquatic Chronic 2, H411	> 0.005 – < 0.05
reaction mass of 5-chloro-2- methyl-2H-isothiazol-3-one and 2-methyl-2H-isothiazol-3- one (3:1)	55965-84-9	Acute Tox. 3, H301 Acute Tox. 2, H310 Acute Tox. 2, H330 Skin Corr. 1C, H314 Eye Dam. 1, H318 Skin Sens. 1A, H317 Aquatic Acute 1, H400 Aquatic Chronic 1, H410	> 0.00015 – < 0.0015
Glycerine	56-81-5 200-289-5 01-2119471987-18-XXXX	Not classified	> 1.0
Pyrogenic (fumed) amorphous silica	112945-52-5 231-545-4 01-2119379499-16-XXXX	Not classified	> 1.0

Further information

Flufenacet	142459-58-3	M-Factor: 100 (acute), 100 (chronic)
Metribuzin	21087-64-9	M-Factor: 10 (acute), 10 (chronic)
1,2-Benzisothiazol-3(2H)-one	2634-33-5	M-Factor: 1 (acute)
reaction mass of 5-chloro-2- methyl-2H-isothiazol-3-one and 2-methyl-2H-isothiazol-3-one (3:1)	55965-84-9	M-Factor: 100 (acute), 100 (chronic)

For the full text of the H-Statements mentioned in this Section, see Section 16.

SECTION 4: FIRST AID MEASURES**4.1 Description of first aid measures****General advice**

Move out of dangerous area. Remove contaminated clothing immediately and dispose of safely. Place and transport victim in stable position (lying sideways).

Inhalation

Move to fresh air. Keep patient warm and at rest. Call a physician or poison control center immediately.

Skin contact

Wash off thoroughly with plenty of soap and water, if available with polyethyleneglycol 400, subsequently rinse with water. If symptoms persist, call a physician.



BACARA TRIPLE

Version 1 / IRL
102000027454

4/13

Revision Date: 26.09.2019
Print Date: 26.09.2019

Eye contact Rinse immediately with plenty of water, also under the eyelids, for at least 15 minutes. Remove contact lenses, if present, after the first 5 minutes, then continue rinsing eye. Get medical attention if irritation develops and persists.

Ingestion Do NOT induce vomiting. Call a physician or poison control center immediately. Rinse mouth.

4.2 Most important symptoms and effects, both acute and delayed

Symptoms The absorption of this product into the body may lead to the formation of methaemoglobine that, in sufficient concentration, causes cyanosis.

If large amounts are ingested, the following symptoms may occur:

Headache, Nausea, Dizziness, Drowsiness, Tiredness, Breathing difficulties, tachycardia

Symptoms and hazards refer to effects observed after intake of significant amounts of the active ingredient(s).

4.3 Indication of any immediate medical attention and special treatment needed

Risks Danger of formation of methaemoglobin.

Treatment Treat symptomatically. In case of methaemoglobinemia, oxygen and specific antidotes (methylene blue/ toluidine blue) should be given. In case of ingestion gastric lavage should be considered in cases of significant ingestions only within the first 2 hours. However, the application of activated charcoal and sodium sulphate is always advisable. There is no specific antidote.

SECTION 5: FIREFIGHTING MEASURES

5.1 Extinguishing media

Suitable Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide.

Unsuitable High volume water jet

5.2 Special hazards arising from the substance or mixture Dangerous gases are evolved in the event of a fire., In the event of fire the following may be released:, Hydrogen cyanide (hydrocyanic acid), Hydrogen fluoride, Carbon monoxide (CO), Nitrogen oxides (NOx), Sulphur oxides

5.3 Advice for firefighters

Special protective equipment for firefighters In the event of fire and/or explosion do not breathe fumes. In the event of fire, wear self-contained breathing apparatus.

Further information Contain the spread of the fire-fighting media. Do not allow run-off from fire fighting to enter drains or water courses.



BACARA TRIPLE

Version 1 / IRL
102000027454

5/13

Revision Date: 26.09.2019
Print Date: 26.09.2019

SECTION 6: ACCIDENTAL RELEASE MEASURES

6.1 Personal precautions, protective equipment and emergency procedures

Precautions Avoid contact with spilled product or contaminated surfaces. Use personal protective equipment.

6.2 Environmental precautions Do not allow to get into surface water, drains and ground water.

6.3 Methods and materials for containment and cleaning up

Methods for cleaning up Soak up with inert absorbent material (e.g. sand, silica gel, acid binder, universal binder, sawdust). Collect and transfer the product into a properly labelled and tightly closed container. Clean contaminated floors and objects thoroughly, observing environmental regulations.

Additional advice Check also for any local site procedures.

6.4 Reference to other sections Information regarding safe handling, see section 7.
Information regarding personal protective equipment, see section 8.
Information regarding waste disposal, see section 13.

SECTION 7: HANDLING AND STORAGE

7.1 Precautions for safe handling

Advice on safe handling No specific precautions required when handling unopened packs/containers; follow relevant manual handling advice. Use only in area provided with appropriate exhaust ventilation.

Advice on protection against fire and explosion Keep away from heat and sources of ignition.

Hygiene measures Avoid contact with skin, eyes and clothing. Keep working clothes separately. Wash hands before breaks and immediately after handling the product. Remove soiled clothing immediately and clean thoroughly before using again.

7.2 Conditions for safe storage, including any incompatibilities

Requirements for storage areas and containers Store in a place accessible by authorized persons only. Store in original container. Keep containers tightly closed in a dry, cool and well-ventilated place. Keep away from direct sunlight. Protect from freezing.

Advice on common storage Keep away from food, drink and animal feedingstuffs.

Suitable materials HDPE (high density polyethylene)

7.3 Specific end use(s) Refer to the label and/or leaflet.

SECTION 8: EXPOSURE CONTROLS/PERSONAL PROTECTION

8.1 Control parameters

Components	CAS-No.	Control parameters	Update	Basis
------------	---------	--------------------	--------	-------

**BACARA TRIPLE**Version 1 / IRL
102000027454

6/13

Revision Date: 26.09.2019

Print Date: 26.09.2019

Diflufenican	83164-33-4	5.5 mg/m ³ (TWA)		OES BCS*
Flufenacet	142459-58-3	0.3 mg/m ³ (SK-SEN)		OES BCS*
Metribuzin	21087-64-9	5 mg/m ³ (TWA)	2011	ELV (IE)
Metribuzin	21087-64-9	0.36 mg/m ³ (SK-SEN)		OES BCS*
Pyrogenic (fumed) amorphous silica (Total inhalable dust.)	112945-52-5	6 mg/m ³ (TWA)	2011	ELV (IE)
Pyrogenic (fumed) amorphous silica (Respirable dust.)	112945-52-5	2.4 mg/m ³ (TWA)	2011	ELV (IE)

*OES BCS: Internal Bayer AG, Crop Science Division "Occupational Exposure Standard"

8.2 Exposure controls**Personal protective equipment**

In normal use and handling conditions please refer to the label and/or leaflet. In all other cases the following recommendations would apply.

Respiratory protection

Respiratory protection is not required under anticipated circumstances of exposure.

Respiratory protection should only be used to control residual risk of short duration activities, when all reasonably practicable steps have been taken to reduce exposure at source e.g. containment and/or local extract ventilation. Always follow respirator manufacturer's instructions regarding wearing and maintenance.

Hand protection

Please observe the instructions regarding permeability and breakthrough time which are provided by the supplier of the gloves. Also take into consideration the specific local conditions under which the product is used, such as the danger of cuts, abrasion, and the contact time.

Wash gloves when contaminated. Dispose of when contaminated inside, when perforated or when contamination on the outside cannot be removed. Wash hands frequently and always before eating, drinking, smoking or using the toilet.

Material	Nitrile rubber
Rate of permeability	> 480 min
Glove thickness	> 0.4 mm
Protective index	Class 6
Directive	Protective gloves complying with EN 374.

Eye protection

Wear goggles (conforming to EN166, Field of Use = 5 or equivalent).

Skin and body protection

Wear standard coveralls and Category 3 Type 4 suit.

If there is a risk of significant exposure, consider a higher protective type suit.

Wear two layers of clothing wherever possible. Polyester/cotton or cotton overalls should be worn under chemical protection suit and should be professionally laundered frequently.

**BACARA TRIPLE**Version 1 / IRL
102000027454

7/13

Revision Date: 26.09.2019
Print Date: 26.09.2019

SECTION 9: PHYSICAL AND CHEMICAL PROPERTIES**9.1 Information on basic physical and chemical properties**

Form	suspension
Colour	white to beige
Odour	weakly pungent
pH	4.0 - 6.0 (100 %) (23 °C)
Flash point	> 96 °C
Auto-ignition temperature	445 °C
Density	1.17 g/cm ³ (20 °C)
Partition coefficient: n-octanol/water	Diflufenican: log Pow: 4.2 Flufenacet: log Pow: 3.2 Metribuzin: log Pow: 1.6
Viscosity, kinematic	294 mm ² /s (40 °C) Shear rate of 20/sec 102 mm ² /s (40 °C) Shear rate of 100/sec
Surface tension	37 mN/m (25 °C) Determined in the undiluted form.
Impact sensitivity	Not impact sensitive.
Oxidizing properties	No oxidizing properties
Explosivity	Not explosive
9.2 Other information	Further safety related physical-chemical data are not known.

SECTION 10: STABILITY AND REACTIVITY**10.1 Reactivity****Thermal decomposition** Stable under normal conditions.**10.2 Chemical stability** Stable under recommended storage conditions.**10.3 Possibility of hazardous reactions** No hazardous reactions when stored and handled according to prescribed instructions.**10.4 Conditions to avoid** Extremes of temperature and direct sunlight.**10.5 Incompatible materials** Store only in the original container.**10.6 Hazardous decomposition products** No decomposition products expected under normal conditions of use.



BACARA TRIPLE

Version 1 / IRL
102000027454

8/13

Revision Date: 26.09.2019
Print Date: 26.09.2019

SECTION 11: TOXICOLOGICAL INFORMATION

11.1 Information on toxicological effects

Acute oral toxicity	ATE (Mix) (Rat) > 2,000 mg/kg calculated
Acute inhalation toxicity	LC50 (Rat) > 4.19 mg/l Exposure time: 4 h Highest attainable concentration. Determined in the form of a respirable aerosol. Test conducted with a similar formulation.
Acute dermal toxicity	LD50 (Rat) > 2,000 mg/kg Test conducted with a similar formulation.
Skin corrosion/irritation	No skin irritation (Rabbit) Test conducted with a similar formulation.
Serious eye damage/eye irritation	No eye irritation (Rabbit) Test conducted with a similar formulation.
Respiratory or skin sensitisation	Skin: Non-sensitizing. (Mouse) OECD Test Guideline 429, local lymph node assay (LLNA) Test conducted with a similar formulation.

Assessment STOT Specific target organ toxicity – single exposure

Diflufenican: Based on available data, the classification criteria are not met.

Flufenacet: Based on available data, the classification criteria are not met.

Metribuzin: Based on available data, the classification criteria are not met.

Assessment STOT Specific target organ toxicity – repeated exposure

Diflufenican did not cause specific target organ toxicity in experimental animal studies.

Flufenacet caused neurobehavioral effects and/or neuropathological changes in animal studies.

Metribuzin caused specific target organ toxicity in experimental animal studies in the following organ(s):
Liver, Kidney.

Assessment mutagenicity

Diflufenican was not mutagenic or genotoxic in a battery of in vitro and in vivo tests.

Flufenacet was not mutagenic or genotoxic in a battery of in vitro and in vivo tests.

Metribuzin was not mutagenic or genotoxic based on the overall weight of evidence in a battery of in vitro and in vivo tests.

Assessment carcinogenicity

Diflufenican was not carcinogenic in lifetime feeding studies in rats and mice.

Flufenacet was not carcinogenic in lifetime feeding studies in rats and mice.

Metribuzin was not carcinogenic in lifetime feeding studies in rats and mice.

Assessment toxicity to reproduction

Diflufenican did not cause reproductive toxicity in a two-generation study in rats.

Flufenacet did not cause reproductive toxicity in a two-generation study in rats.

Metribuzin caused reproduction toxicity in a two-generation study in rats only at dose levels also toxic to the parent animals. The reproduction toxicity seen with Metribuzin is related to parental toxicity.

Assessment developmental toxicity

Diflufenican did not cause developmental toxicity in rats and rabbits.

Flufenacet caused developmental toxicity only at dose levels toxic to the dams. The developmental



BACARA TRIPLE

Version 1 / IRL
102000027454

9/13

Revision Date: 26.09.2019
Print Date: 26.09.2019

effects seen with Flufenacet are related to maternal toxicity.
Metribuzin caused developmental toxicity only at dose levels toxic to the dams. The developmental effects seen with Metribuzin are related to maternal toxicity.

Aspiration hazard

Based on available data, the classification criteria are not met.

SECTION 12: ECOLOGICAL INFORMATION

12.1 Toxicity

Toxicity to fish

LC50 (*Lepomis macrochirus* (Bluegill sunfish)) 2.13 mg/l
Exposure time: 96 h
The value mentioned relates to the active ingredient flufenacet.

LC50 (*Oncorhynchus mykiss* (rainbow trout)) > 109 µg/l
Exposure time: 96 h
The value mentioned relates to the active ingredient diflufenican.
Aquatic toxicity is unlikely due to low solubility.

LC50 (*Oncorhynchus mykiss* (rainbow trout)) 74.6 mg/l
Exposure time: 96 h
The value mentioned relates to the active ingredient metribuzin.

Toxicity to aquatic invertebrates

EC50 (*Daphnia magna* (Water flea)) 30.9 mg/l
Exposure time: 48 h
The value mentioned relates to the active ingredient flufenacet.

EC50 (*Daphnia magna* (Water flea)) > 240 µg/l
Exposure time: 48 h
The value mentioned relates to the active ingredient diflufenican.
No acute toxicity was observed at its limit of water solubility.

EC50 (*Daphnia magna* (Water flea)) 49.6 mg/l
Exposure time: 48 h
The value mentioned relates to the active ingredient metribuzin.

Toxicity to aquatic plants

EC50 (*Raphidocelis subcapitata* (freshwater green alga)) 9,36 µg/l
Growth rate; Exposure time: 72 h
Test conducted with a similar formulation.

NOEC (*Raphidocelis subcapitata* (freshwater green alga)) 0,477 µg/l
Growth rate; Exposure time: 72 h
Test conducted with a similar formulation.

EC50 (*Lemna gibba* (gibbous duckweed)) 49,3 µg/l
Growth rate; Exposure time: 7 d
Test conducted with a similar formulation.

12.2 Persistence and degradability

Biodegradability

Diflufenican:
Not rapidly biodegradable
Flufenacet:
Not rapidly biodegradable
Metribuzin:



BACARA TRIPLE

Version 1 / IRL
102000027454

10/13

Revision Date: 26.09.2019
Print Date: 26.09.2019

Koc Not rapidly biodegradable
Diflufenican: Koc: 3417
Flufenacet: Koc: 202
Metribuzin: Koc: 24 - 106

12.3 Bioaccumulative potential

Bioaccumulation Diflufenican: Bioconcentration factor (BCF) 1,596
Does not bioaccumulate.
Flufenacet: Bioconcentration factor (BCF) 71
Does not bioaccumulate.
Metribuzin:
Does not bioaccumulate.

12.4 Mobility in soil

Mobility in soil Diflufenican: Slightly mobile in soils
Flufenacet: Moderately mobile in soils
Metribuzin: Mobile in soils

12.5 Results of PBT and vPvB assessment

PBT and vPvB assessment Diflufenican: This substance is not considered to be persistent, bioaccumulative and toxic (PBT). This substance is not considered to be very persistent and very bioaccumulative (vPvB).
Flufenacet: This substance is not considered to be persistent, bioaccumulative and toxic (PBT). This substance is not considered to be very persistent and very bioaccumulative (vPvB).
Metribuzin: This substance is not considered to be persistent, bioaccumulative and toxic (PBT). This substance is not considered to be very persistent and very bioaccumulative (vPvB).

12.6 Other adverse effects

Additional ecological information No other effects to be mentioned.

SECTION 13: DISPOSAL CONSIDERATIONS

13.1 Waste treatment methods

Product In accordance with current regulations and, if necessary, after consultation with the site operator and/or with the responsible authority, the product may be taken to a waste disposal site or incineration plant.

Contaminated packaging Not completely emptied packagings should be disposed of as hazardous waste.

Waste key for the unused product 02 01 08* agrochemical waste containing hazardous substances

SECTION 14: TRANSPORT INFORMATION

ADR/RID/ADN
14.1 UN number

3082



BACARA TRIPLE

Version 1 / IRL
102000027454

11/13
Revision Date: 26.09.2019
Print Date: 26.09.2019

14.2 Proper shipping name	ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID, N.O.S. (FLUFENACET, METRIBUZIN SOLUTION)
14.3 Transport hazard class(es)	9
14.4 Packaging Group	III
14.5 Environm. Hazardous Mark	YES
Hazard no.	90

This classification is in principle not valid for carriage by tank vessel on inland waterways. Please refer to the manufacturer for further information.

IMDG

14.1 UN number	3082
14.2 Proper shipping name	ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID, N.O.S. (FLUFENACET, METRIBUZIN SOLUTION)
14.3 Transport hazard class(es)	9
14.4 Packaging Group	III
14.5 Marine pollutant	YES

IATA

14.1 UN number	3082
14.2 Proper shipping name	ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID, N.O.S. (FLUFENACET, METRIBUZIN SOLUTION)
14.3 Transport hazard class(es)	9
14.4 Packaging Group	III
14.5 Environm. Hazardous Mark	YES

14.6 Special precautions for user

See sections 6 to 8 of this Safety Data Sheet.

14.7 Transport in bulk according to Annex II of MARPOL and the IBC Code

No transport in bulk according to the IBC Code.

SECTION 15: REGULATORY INFORMATION

15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture

Republic of Ireland Regulations

This material may be subject to some or all of the following regulations (and any subsequent amendments). Users must ensure that any uses and restrictions as indicated on the label and/or leaflet are followed.

Supply and Use

European Communities (Prohibition of Certain Active Substances in Plant Protection Products) Regulations 1981 (SI No 320/1981)

European Communities (Authorization, Placing on the Market, Use and Control of Plant Protection Products) Regulations 2003 (SI No 83/2003)

European Communities (Classification, Packaging and Labelling of Plant Protection Products and Biocide Products) Regulations 2001 (SI No 624/2001)

2010 Code of Practice for the Safety, Health and Welfare at Work (Chemical Agents) Regulations, 2001



BACARA TRIPLE

Version 1 / IRL
102000027454

12/13
Revision Date: 26.09.2019
Print Date: 26.09.2019

(SI No 619/2001)

Waste Treatment

Landfill Directive
Regulation on Substances That Deplete the Ozone Layer 1994 (EEC/3093/94)

Further information

WHO-classification: III (Slightly hazardous)

15.2 Chemical safety assessment

A chemical safety assessment is not required.

SECTION 16: OTHER INFORMATION

Text of the hazard statements mentioned in Section 3

H301	Toxic if swallowed.
H302	Harmful if swallowed.
H310	Fatal in contact with skin.
H314	Causes severe skin burns and eye damage.
H315	Causes skin irritation.
H317	May cause an allergic skin reaction.
H318	Causes serious eye damage.
H330	Fatal if inhaled.
H373	May cause damage to organs through prolonged or repeated exposure.
H400	Very toxic to aquatic life.
H410	Very toxic to aquatic life with long lasting effects.
H411	Toxic to aquatic life with long lasting effects.
H412	Harmful to aquatic life with long lasting effects.

Abbreviations and acronyms

ADN	European Agreement concerning the International Carriage of Dangerous Goods by Inland Waterways
ADR	European Agreement concerning the International Carriage of Dangerous Goods by Road
ATE	Acute toxicity estimate
CAS-Nr.	Chemical Abstracts Service number
Conc.	Concentration
EC-No.	European community number
ECx	Effective concentration to x %
EINECS	European inventory of existing commercial substances
ELINCS	European list of notified chemical substances
ELV	Exposure Limit Value
EN	European Standard
EU	European Union
IATA	International Air Transport Association
IBC	International Code for the Construction and Equipment of Ships Carrying Dangerous Chemicals in Bulk (IBC Code)
ICx	Inhibition concentration to x %
IMDG	International Maritime Dangerous Goods
LCx	Lethal concentration to x %
LDx	Lethal dose to x %
LOEC/LOEL	Lowest observed effect concentration/level



BACARA TRIPLE

Version 1 / IRL
102000027454

13/13
Revision Date: 26.09.2019
Print Date: 26.09.2019

MARPOL	MARPOL: International Convention for the prevention of marine pollution from ships
N.O.S.	Not otherwise specified
NOEC/NOEL	No observed effect concentration/level
OECD	Organization for Economic Co-operation and Development
RID	Regulations concerning the International Carriage of Dangerous Goods by Rail
SI	Statutory Instrument
TWA	Time weighted average
UN	United Nations
WHO	World health organisation

Changes since the last version are highlighted in the margin. This version replaces all previous versions.